MANE Veradermics, Incorporated
USHealthcareAs of 2026-07-02
Why MANE matters now
Veradermics, Incorporated (MANE) is a US stock in Healthcare. The latest InvestLog snapshot shows $129.74 with +0.98% on the session and $5.42B in market capitalization; recent performance reads 1-month -6.20% and YTD +148.66%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-27.2M, and EPS of $-0.80. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.2%.
The latest indexable market news headline is "Biotech ETF Index Surges 10% After Rebalance" from ETF Trends.
Additional event context on this page matters because analyst consensus is Buy with a median target of $105.50. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.94
P/S
0.00
EV/EBITDA
-69.62
DCF Value
$0.60
FCF Yield
-1.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-95.4%
ROA
-13.7%
ROIC
-15.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-27.2M | $-0.80 |
| Q4 2025 | $0.00 | $-21.8M | $-0.76 |
| FY 2025 | $0.00 | $-70.0M | $-2.38 |
| Q4 2024 | $0.00 | $-5.7M | $-0.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$105.50
Target (Median)
$105.50
Target Range
$75.00 - $136.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.58
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.